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Pelvic inﬂammatory disease (PID), one of the most common infections in nonpregnant women of reproductive age, remains
an important public health problem. It is associated with major long-term sequelae, including tubal factor infertility, ectopic
pregnancy, and chronic pelvic pain. In addition, treatment of acute PID and its complications incurs substantial health care
costs. Prevention of these long-term sequelae is dependent upon development of treatment strategies based on knowledge of
the microbiologic etiology of acute PID. It is well accepted that acute PID is a polymicrobic infection. The sexually transmitted
organisms, Neisseria gonorrhoeae and Chlamydia trachomatis, are present in many cases, and microorganisms comprising the
endogenous vaginal and cervical ﬂora are frequently associated with PID. This includes anaerobic and facultative bacteria, similar
to those associated with bacterial vaginosis. Genital tract mycoplasmas, most importantly Mycoplasma genitalium,h a v er e c e n t l y
also been implicated as a cause of acute PID. As a consequence, treatment regimens for acute PID should provide broad spectrum
coverage that is eﬀective against these microorganisms.
1.Introduction
Pelvic inﬂammatory disease (PID) is a spectrum of upper
genitaltractinfectionsthatincludesendometritis,salpingitis,
tuboovarian abscess, and/or pelvic peritonitis [1]. Typically,
acute PID is caused by ascending spread of microorganisms
from the vagina and/or endocervix to the endometrium,
fallopian tubes, and/or adjacent structures [1–3]. Acute salp-
ingitis is the most important component of the PID spec-
trum because of its impact on future fertility [3].
PID is one of the most frequent and important infections
that occur among nonpregnant women of reproductive age
and remains a major public health problem [4–8]. Among
women, it is the most signiﬁcant complication of sexually
transmitted diseases/infections. Unfortunately, women who
acquireacutePIDareatriskforlong-termsequelaeincluding
tubal factor infertility, ectopic pregnancy, chronic pelvic
pain, and recurrent PID [9–13]. In addition, the estimated
annual health care cost for PID and its complications in the
United States is over $2 billion [7].
Currently, an estimated 770,000 cases of acute PID are
diagnosed annually in the United States. A recent analysis
by the Centers for Disease Control and Prevention (CDC)
of trends in the incidence of PID demonstrated that from
1985 to 2001 rates of both hospitalized and ambulatory
cases of acute PID declined (68% and 47%, resp.) [6]. This
good news is mitigated by two factors. Recently, subclinical
PID has been recognized as an important entity which is
common among women with lower genital tract infections,
especially Chlamydia trachomatis, Neisseria gonorrhoeae,a n d
bacterial vaginosis (BV) [14, 15]. Subclinical PID is as likely
as clinically recognized acute PID and is responsible for a
greater proportion of PID-related sequelae than clinically
recognized disease [16]. Secondly, is concern that the con-
tinued increases in C. trachomatis infections reported by the
CDC in the United States will be associated with an increase
in both clinical and subclinical PID.
Overthepast25years,importantadvanceshaveoccurred
in understanding the etiology, pathogenesis, and treatment
of acute PID. As a result, major paradigm shifts have
occurred in our approach to the treatment of acute PID.
In the past PID was believed to be a monoetiologic infec-
tion, primarily caused by Neisseria gonorrhoeae.T o d a y ,t h e
polymicrobic etiology of PID is well established and has led
to utilization of broad spectrum antimicrobial regimens for
treatment of acute PID [1, 2, 17, 18].2 Infectious Diseases in Obstetrics and Gynecology
2. Etiology of PID
Prevention of the signiﬁcant long-term complications asso-
ciated with PID requires development of eﬀective treatment
strategies. Such treatment regimens are dependent upon
an understanding of the microbiologic etiology of acute
PID. However, elucidation of the etiology of PID has
been hindered by several factors. Firstly, most studies have
utilized specimens obtained from the lower genital tract
(primarily cervix) and not the upper genital tract (endome-
trial cavity, fallopian tubes) which is the actual site of
infection.Secondly,mostinvestigationsprimarilyfocusedon
the sexually transmitted pathogens N. gonorrhoeae and/or
C. trachomati,s and few studies have assessed the role of
non-STD pathogens, especially anaerobic bacteria. Thirdly,
even fewer investigations have addressed the putative role of
Mycoplasma genitalium in the etiology of PID.
PID results from the intracannicular ascending spread
of microorganisms from the cervix and/or vagina into the
upper genital tract. Prior to the mid-1970s, PID was be-
lieved to be a monoetiologic infection due primarily to N.
gonorrhoeae. Based initially upon culdocentesis studies of
peritoneal ﬂuid (Figure 1) and subsequently studies utiliz-
ing laparoscopy and/or endometrial aspirations to obtain
specimens from the upper genital tract (Table 1)c a m e
the recognition that the etiology of acute PID is polymi-
crobic with a wide variety of microorganisms involved
[1, 2, 19–41]. Included among these are N. gonorrhoeae,
C. trachomatis, genital tract mycoplasmas (particularly M.
genitalium), anaerobic and aerobic bacteria which comprise
the endogenous vaginal ﬂora (e.g., Prevotella species, black-
pigmented Gram-negative anaerobic rods, Peptostreptococci
sp., Gardnerella vaginalis, Escherichia coli, Haemophilus
inﬂuenzae, and aerobic streptococci).
Investigations by our group conducted in the 1980s
that utilized laparoscopy and/or endometrial aspirations to
obtain upper genital tract specimens demonstrated that
approximately two-thirds of acute PID cases were associated
with N. gonorrhoeae and/or C. trachomatis (Figure 2). In
nearly one-third only anaerobic and aerobic bacteria are
recovered. In addition, half of the women with N. gonor-
rhoeae and/or C. trachomatis had concomitant anaerobic
and/or aerobic bacteria recovered. More recently, in the
Pelvic Inﬂammatory Disease Evaluation and Clinical Health
(PEACH) study, the largest treatment trial of mild to
moderate acute PID in the US, N. gonorrhoeae and C.
trachomatis were recovered in less than one-third of patients
[42].
Many of the nongonococcal, nonchlamydial microor-
ganisms recovered from the upper genital tract in acute
PID are similar to those associated with bacterial vaginosis
(BV), a complex perturbation of the vaginal ﬂora leading
to loss of hydrogen peroxide producing lactobacillus and
overgrowth of G. vaginalis, Prevotella sp. (especially P.
bivius, P. disiens,a n dP. capillosus), Mobiluncus sp., black-
pigmented anaerobic Gram-negative rods, alpha-hemolytic
streptococci, and mycoplasmas [43]. Multiple investigations
havedemonstratedanassociationbetweenBVandacutePID
[31, 35, 43–51]. In addition, use of a broad-range 16SrDNA
polymerase chain reaction to identify uncultivable bacteria
has identiﬁed bacterial 16S sequences of anaerobic bacteria
associated with BV in the fallopian tube of women with
laparoscopically conﬁrmed acute PID [52].
Although M. genitalium was identiﬁed in the early 1980s
as a cause of nongonococcal urethritis in men, its role in
genital tract infections in women remained unclear, due in
large part to diﬃculty in culturing this organism. With the
advent of polymerase chain reaction (PCR) technology, M.
genitalium has been associated with cervicitis [53, 54]a n d
h a sb e e nd e m o n s t r a t e da sa ne t i o l o g i ca g e n ti nn o n g o n o c o c -
cal nonchlamydial PID [36–39]. Haggerty et al. detected M.
genitalium in 15% of women in the PEACH study [40], a
rate similar to that seen in UK women (13%) [37]a n dw e s t
African women (16%) [36]. These rates of M. genitalium are
similar to those seen for C. trachomatis and N. gonorrhoeae
in the PEACH study of urban women in the United States.
A recent analysis from the PEACH study noted that rates
of short-term failure (persistent endometritis and pelvic
pain), infertility, recurrent PID, and chronic pelvic pain
were high among women with endometrial M. genitalium at
baseline [40]. Subsequently, it has been demonstrated that
women with M. genitalium infection (similar to those with
chlamydial infection) present with fewer clinical signs and
symptoms ofacutePID thanthose withgonococcalinfection
[41]. A pathogenic role of M. genitalium i nP I Di sf u r t h e r
supported by studies demonstrating that M. genitalium
induces salpingitis in experimental monkey studies [55]a n d
adheres to human fallopian tube epithelial cells, in organ
culture, causing damage to ciliated cells [56].
Recent attention has focused on subclinical PID. This
term was initially applied to women with documented tubal
factor infertility associated with evidence of chronic inﬂam-
matory residua characteristic of PID who denied a history of
being diagnosed or treated for acute PID [15]. Preliminary
work by our group has suggested that the microorganisms
(e.g., N. gonorrhoeae, C. trachomatis, and bacterial vaginosis)
associated with subclinical PID are the same putative agents
recovered from women with clinically apparent acute PID
[14].
3. Treatment Concepts
The therapeutic goals for treatment of acute PID include
both short-term outcomes such as clinical cure and micro-
biologic cure and preventions of long-term sequelae such
as infertility, ectopic pregnancy, recurrent infection, and
chronic pelvic pain. Although the incidence rates of PID
have declined, no reduction in the adverse reproductive
outcomes associated with PID (infertility, ectopic pregnancy,
and chronic pelvic pain) has been demonstrated [17].
While some antibiotic regimens have been successful in
producing initial clinical and microbiologic cure with short-
term followup, only a few studies have determined the eﬃ-
cacyofthesetreatmentregimensforeliminatingendometrial
or fallopian tube infection. In addition, few studies have
attempted to assess the incidence of long-term sequelae (e.g.,
tubal factor infertility, ectopic pregnancy and chronic pelvicInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Recovery of microorganisms from the upper genital tract of women with acute PID.
Study Number of patients Chlamydia trachomatis Neisseria gonorrhoeae Anaerobic and aerobic
bacteria
Sweet [26–29] 380 68 (18%) 172 (45%) 267 (70%)
Wasserheit [30] 23 11 (44%) 8 (35%) 11 (45%)
Heinonen [31] 25 10 (40%) 4 (16%) 17 (68%)
Paavonen [32] 35 12 (34%) 4 (11%) 24 (69%)
Brunham [33] 50 21 (42%) 8 (16%) 10 (20%)
Soper [34]8 4 a 1 (1.2%) 32 (38%) 12 (13%)
51b 6 (7.4%) 49 (98%) 16 (32%) Hillier [35]
85a 3 (4%) 16 (19%) 43 (50%)
178b 23 (13%) 44 (25%) 168 (94%)
278c 27 (9.9%) 37 (13.4%) 170 (61%)
Haggerty [36]4 5 c,d 12 (26.5%) 15 (33.3%) e
Total 1234 194 (15.7%) 389 (31.5%) 770 (62%)
aFallopian tube, cul-de-sac.
bEndometrial cavity.
cClinically diagnosed acute PID.
dHistologic endometritis.
eNot available as total: anaerobic Gram-negative rods 31.7%; anaerobic Gram-positive cocci 22%; Gardnerella vaginalis 30.5%.
Reprinted with permission. Sweet [3].
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Figure 1: Microbiologic Etiology of Acute PID as determined by Culdocentesis, (based on references [20–25]).
pain) following treatment with these antibiotic regimens
[1, 10, 11, 42].
In the preantibiotic era most cases of acute PID managed
by conservative supportive care resolved spontaneously with
studies demonstrating that approximately 85% of patients
with acute PID improved clinically without the need for sur-
gical intervention. The other 15% had prolonged or progres-
sive symptoms requiring surgical intervention. In addition,
there was approximately a 1% mortality rate. The introduc-
tion of antibiotics into clinical practice led to improvement
in the prognosis for acute PID, and mortality was nearly
eliminated. Studies assessing fertility rates following acute
PIDshowedageneralimprovementinfertilitywiththemean
pregnancy rate increasing from 27.9% (range 24%–43%)
in the preantibiotic era to 73.1% (range 24%–81%) in the
post-antibiotic era [57]. While this ﬁnding is satisfying, these
results are still far from adequate.
As reviewed above, PID is a polymicrobial infection.
According to the CDC, PID treatment regimens must pro-
vide broad spectrum coverage of likely pathogens [1]. Sub-
stantial evidence supports the role of N. gonorrhoeae, C.
trachomatis, anaerobic bacteria, and facultative bacteria in
the pathogenesis of acute PID [1–5, 9]. Not only are N.
gonorrhoeae and C. trachomatis frequently recovered from
the upper genital tract in women with PID, excellent data
demonstrates the role these pathogens play in producing
tubaldamageandinthe developmentofthe adverse sequelae
of PID (e.g., infertility, ectopic pregnancy) [57–60]. Thus,
antimicrobial regimens for the treatment of acute PID
must be eﬀective against these STD organisms. While some4 Infectious Diseases in Obstetrics and Gynecology
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Figure 2: Microbiology of acute PID.
antimicrobial regimens that do not provide adequate cover-
age against N. gonorrhoeae and/or C. trachomatis have been
shown to have excellent clinical cure rates, microbiologic
cure rates are less impressive (or lacking), and long-term
outcome data are not available [17, 18, 61–64]. The CDC
in its 2010 treatment recommendations [1] notes that all
regimens used to treat acute PID should provide adequate
coverage against N. gonorrhoeae and C. trachomatis, as they
are both commonly present and have the propensity to
produce tubal damage directly (N. gonorrhoeae) or indirectly
via the host immune response (C. trachomatis).
The putative role of nongonococcal nonchlamydial bac-
teria, especially anaerobes and more recently M. genitalium,
in the pathogenesis of acute PID and whether antimicrobial
regimens for treatment of PID should provide coverage
against these microorganisms is more controversial. Some
propose that anaerobic coverage is only required in patients
with severe PID [2], especially those with tuboovarian ab-
scesses. Others suggest that anaerobic coverage should be
provided to all women with acute PID [1]. Clearly anaerobic
bacteria have been demonstrated in the upper genital tract
of women with acute PID with anaerobic bacteria recovered
from the upper genital tract in 13% to 78% of women with
PID[28–35].Inaddition,anaerobes(e.g.,Bacteroidesfragilis)
have caused tubal damage in vitro studies [1].
Bacterial vaginosis (BV) has been noted to be frequently
present in women presenting with acute PID [1, 43, 51]. In
thePEACHstudy,two-thirdsofthewomenhadconcomitant
BV [45]. Moreover, in the PEACH study women with
acute endometritis on endometrial biopsy were commonly
infected with BV-associated microorganisms in their upper
genital tract (G. vaginalis 30.5%, anaerobic Gram-negative
rods 31.7%, and anaerobic Gram-positive cocci 22%) [45].
Multiple previous studies [31, 43–49] support the ﬁndings
of the PEACH study conclusions that BV is associated
with acute PID. In addition, the Gyn Infectious Follow-
through (GIFT) study, a longitudinal study of women
with BV, demonstrated that the presence of BV-related
microorganisms signiﬁcantly increased the risk for acquiring
PID [65].
The PEACH Study authors concluded that BV-associated
organisms are very commonly present in women with mild-
to-moderately severe PID and suggested that treatment reg-
imens for all women with PID include antimicrobial agents
eﬀective against anaerobes associated with BV. In a similar
vein, the CDC notes that until treatment regimens that
do not adequately cover these BV-associated anaerobes have
been demonstrated in clinical trial to prevent the long-term
s e q u e l a eo fP I Da se ﬃcaciously as regimens which provide
eﬀective coverage for these microbes, use of regimens with
antianaerobic activity should be considered.
Limited data suggest that failure to cover anaerobes in
women with acute PID may predispose them to devel-
opment of long-term sequelae. In the 1970s when single
agent monotherapy was the standard for treatment of PID,
Chow et al. noted that tuboovarian abscesses developed
in PID patients being treated solely with tetracycline [19].
Subsequently, our group reported that anaerobic bacteria
persisted in the endometrial cavities of women with PID
treatedwithciproﬂoxacin despite apparentclinical cure[62].
This ﬁnding is analogous to the ﬁnding by our group that
failure to include an antimicrobial agent eﬀective against C.
trachomatis resulted in persistent chlamydial infection in the
endometrial cavity [61]. In a proof of concept study, Eckert
and coworkers demonstrated that women at high risk for
PID but without a clinical diagnosis of PID improved with
antimicrobial regimens that provided anaerobic coverage
as measured by clinical improvement and resolution of
histologic endometritis [66].
Neither the 2010 CDC sexually transmitted disease treat-
ment guidelines [1] nor the 2007 European guideline for
management of pelvic inﬂammatory disease [2]s t r o n g l y
advocate for anaerobic coverage in the treatment of acute
PID. However, because of the substantial evidence that
anaerobes are commonly recovered from women with mild-
to-moderate and severe PID, and that failure to eradicateInfectious Diseases in Obstetrics and Gynecology 5
anaerobes from the upper genital tract may lead to tubal
damage, it seems prudent to do so. Firstly, as noted above,
until those regimens that do not provide adequate anaerobic
coverage have been shown to prevent adverse sequelae as
well as those that do, it seems advisable to provide anaerobic
coverage. A second strong reason for providing anaerobic
coverage is the frequent (up to 70%) occurrence of BV in
women with PID [50]. Thirdly, anaerobes are widely recog-
nized as important pathogens in severe PID [67].SeverePID,
as determined by laparoscopy, not clinically, is an important
determinant of future infertility [10, 68]. Thus, unless severe
tubal disease has been excluded at laparoscopy, coverage for
anaerobes may have important implications for the future
reproductive health of these women.
On the other hand, reservation regarding the need for
anaerobic coverage for acute PID has been raised. The
PEACH trial [42] compared inpatient with outpatient
treatment regimens in which patients were randomized to
intravenous cefoxitin and doxycycline for a minimum of
48 hours (followed by oral doxycycline for a total of 14
days) or to a single dose of cefoxitin plus 2 weeks of oral
doxycycline. In the ambulatory arm, the single dose of
cefoxitin probably had little impact on anaerobic bacteria,
whereas in the hospitalized arm patients received 48 hours
of anaerobic therapy. No superiority was noted for either
antimicrobial regimen, calling into question the need for
anaerobic therapy in women with mild-to-moderate PID. In
a recent editorial, Eschenbach also questioned a putative role
for anaerobes in the pathogenesis of mild-to-moderate acute
PID and suggested that although anaerobes may be present
in the fallopian tubes, their role in the infectious process is
not entirely clear [69].
However, concern remains about the importance of
anaerobes in the pathogenesis and treatment of acute PID.
Failing to provide anaerobic coverage in PID treatment reg-
imen is problematic because there is limited data in support
of the eﬃcacy of such an approach. Hopefully, additional
studieswilladdressthisissueandprovidefurtherinsightinto
the role of anaerobes in PID.
Although recent reviews of PID treatment trials have
noted that most antibiotic regimens, with the exception of
the doxycycline and metronidazole regimen, result in fairly
similar excellent clinical and microbiologic (primarily cer-
vical N. gonorrhoeae and C. trachomatis)c u r er a t e s[ 17,
18, 63, 64], the search continues for treatment regimen(s)
that optimize prevention of infertility, ectopic pregnancy,
chronic pelvic pain, and recurrent infection. Three major
determinants for preservation of post-PID fertility have been
identiﬁed [3, 69]. These are (1) short duration of symptoms
(<72 hours) prior to institution of therapy; (2) repetitive
episodes of PID; (3) nongonococcal PID [16, 70, 71].
Duration of symptoms is the major determinant of
subsequent infertility. Early diagnosis and treatment are
crucial for preserving fertility and the eﬀectiveness of an-
tibiotic therapy is dependent upon the interval from the
onset of symptoms to the initiation of treatment. In an
updated analysis of the Lund, Sweden cohort of women with
laparoscopically conﬁrmed PID, Hillis and colleagues [71]
demonstratedthatwomentreatedwith ≥3da ysofsymptoms
had a signiﬁcantly greater infertility rate compared to those
<3 days from symptom onset (19.7% versus 8.3%).
In their cohort of laparoscopically conﬁrmed cases of
PID, Westrom and colleagues reported that reinfection was
an important predictor of subsequent tubal factor infertility
[10]. In the most recent update of this cohort with 1,309 PID
cases and 451 control patients who attempted to conceive,
noted that the rate of infertility is directly proportional
to both the number of episodes and severity of tubal
inﬂammationseenatlaparoscopy[11].Eachepisoderoughly
doubles the rate of infertility; with one, two, or three or more
episodes of PID infertility rates were 8.0%, 19.5%, and 40%,
respectively. Among women with a single episode of PID,
future fertility was associated with the severity of PID (at
laparoscopy) ranging from 0.6% with mild disease to 6.2%
and 21.4% for moderate and severe PID, respectively.
Studies based on the Swedish cohort [16, 70]h a v e
also demonstrated that women with chlamydial PID and
nongonococcal nonchlamydial PID fared more poorly after
treatment than those with gonococcal PID. Most likely for
chlamydial PID, it is the delayed commencement of treat-
ment associated with mild slow onset of symptoms. Non-
gonococcal nonchlamydial PID is more often associated with
severe PID which is associated with a worse prognosis for
future fertility.
4. AntimicrobialTreatment Regimens
Despite the controversy regarding the role of anaerobic bac-
teria and M. genitalium in the pathogenesis of acute PID, the
polymicrobicnatureofPIDiswidelyacknowledged[1,2].As
a consequence, PID is treated with antibiotics which provide
coverage against a broad spectrum of potential pathogens. In
2010 the Center for Disease Control and Prevention updated
their Guidelines for treatment of acute PID (Tables 2 and
3). According to the CDC 2010 guidelines, PID treatment
regimens must provide empiric, broad spectrum coverage
of likely pathogens [1]. These guidelines recommend that
all treatment regimens should be eﬀective against N. gonor-
rhoeae and C. trachomatis even in the presence of negative
endocervical screening for these organisms. Although the
CDCnotesthattheneedtoeradicateanaerobesfromwomen
with PID has not been deﬁnitively determined, as reviewed
above, they suggest that until regimens without adequate
coverage for anaerobes have been shown to prevent long-
term sequelae as successfully as those that include anaerobic
coverage, coverage of anaerobes should be considered in the
treatment of acute PID.
As noted by the CDC [1] multiple randomized clinical
treatment trials have demonstrated eﬃcacy of both par-
enteral and oral regimens. In Table 4, the short-term clinical
and microbiologic eﬃcacy of oral and parenteral treatments
regimens for PID are summarized. After excluding the
metronidazole-doxycycline regimen (clinical and microbio-
logic cure rates 75% and 71%, resp.), the pooled clinical cure
ratesrangedfrom88%to99%,andthepooledmicrobiologic
cure rates ranged from 89% to 100%. It is important that
empiric treatment be initiated as soon as a presumptive6 Infectious Diseases in Obstetrics and Gynecology
Table 2: Parenteral treatment recommendations for acute pelvic
inﬂammatory diseasea.
Recommended regimen A
Cefotetan 2g IV every 12 hours
Or
C e f o x i t i n2gI Ve v e r y6h o u r s
Plus
Doxycycline 100mg orally or IV every 12 hours
Recommended regimen B
Clindamycin 900mg IV every 8 hours
Plus
Gentamicin loading dose IV or IM (2mg/Kg body weight)
followed by a maintenance dose (1–5mg/Kg body weight)
every 8 hours.
A single daily dosing (3–5mg/Kg) can be substituted
Alternative parenteral regimen
Ampicillin/sulbactam 3g IV every 6 hours
Plus
Doxycycline 100mg orally or IV every 12 hours
aCDC Sexually Transmitted Diseases Treatment Guidelines 2010 MMWR
2010:59 (no.-RR12): [63–67].
Table 3: Oral treatment recommendations for acute pelvic inﬂam-
matory diseasea.
Recommended regimens
(1) Ceftriaxone 250mg IM in a single dose
Plus
Doxycycline 100mg orally twice a day for 10–14 days
With or without
Metronidazole 500mg orally twice a day for 10–14 days
(2) Cefoxitin 2g IM in a single dose and Probenecid 1g orally
administered concomitantly as a single dose
Plus
Doxycycline 100mg orally twice a day for 10–14 days
With or without
Metronidazole 500mg orally twice a day for 10–14 days
(3) Other parenteral third generation cephalosporins
(e.g., ceftizoxime or cefotaxime) in a single dose
Plus
Doxycycline 100mg orally twice a day for 10–14 days
With or without
Metronidazole 500mg orally twice a day for 10–14 days
aCDC Sexually Transmitted Diseases Treatment Guidelines 2010 MMWR
2010:59 (no.-RR12).
diagnosis of acute PID is made because prevention of long-
term sequelae is determined to a large extent by early ad-
ministration (<72 hours) of appropriate antimicrobial ther-
apy [1]. In addition, selection of a treatment regimen
should consider availability, cost, patient acceptance, and
antimicrobial acceptability [1, 72].
Because parenteral antibiotics do not necessarily require
hospitalization, antibiotic regimens for the treatment of
acute PID are categorized as follows:
(1) regimens requiring more than a single parenteral
dose as initial therapy are “parenteral” and
(2) regimens that are primarily oral with or without an
initial single parenteral dose are considered “oral.”
4.1. Parenteral Treatment. As noted in Table 4,s e v e r a lp a r -
enteral antimicrobial regimens have excellent short-term
clinical and microbiological eﬃcacy. Most of the literature
supports the combination of (1) cefoxitin or cefotetan plus
doxycycline and (2) clindamycin plus gentamicin. These two
regimens remain the parenteral regimens recommended by
the CDC for the treatment of PID. However, cefotetan is not
currently marketed in the United States.
AccordingtotheCDC,thereislimiteddataavailablesup-
porting a role of other second or third generation parenteral
cephalosporins (e.g., ceftizoxime, cefotaxime, or ceftriaxone)
as eﬀective therapy for acute PID and/or replacements for
cefotetan or cefoxitin [1]. Moreover, these antimicrobial
agentsarelessactiveagainstanaerobicbacteriathancefoxitin
or cefotetan.
Intravenous infusion of doxycycline frequently causes
pain and, thus, doxycycline should be administered orally
whenever possible. Fortunately, oral and intravenous admin-
istration of doxycycline provide similar bioavailability [1].
With parenteral regimen A, parenteral therapy can be
discontinued 24 hours after clinical improvement occurs [1].
However, oral doxycycline (100mg twice a day) should be
continued to complete a 14-day course of therapy. In cases
involving tuboovarian abscess, either clindamycin (450mg
orally four times a day) or metronidazole (500mg orally
every 6 hours) should be used for continued therapy in order
toprovidemoreeﬀectivecoverageagainstanaerobicbacteria.
There is concern over the increasing resistance of anaer-
obes, especially the Bacteroides fragilis group, to clindamycin
[73, 74]. However, based on multiple clinical studies and
extensive successful results with clindamycin containing
regimens, clindamycin remains as a component in one of
the recommended parenteral treatment regimens in both the
CDC [1]a n dE u r o p e a n[ 2] guidelines for treatment of PID.
Single dose gentamicin has not been evaluated for the
treatment of acute PID. However, it is eﬃcacious in the
treatment of other pelvic and abdominal infections and is
an option in parenteral regimen B. With this regimen, par-
enteral therapy may be discontinued 24 hours after clinical
therapy. While the CDC suggests that either doxycycline
100mg orally twice a day or clindamycin 450mg orally
f o u rt i m e sad a yt oc o m p l e t eat o t a lo f1 4d a y so ft h e r a p y
may be used [1], in the author’s opinion clindamycin oral
therapy is preferred because of its better anaerobic coverage.
In the presence of severe PID, especially tuboovarian abscess,
clindamycin continued therapy is recommended by the CDC
[1].Infectious Diseases in Obstetrics and Gynecology 7
Table 4: Clinical and microbiologic cure rates for pelvic inﬂammatory disease treatment regimens.
Clinical cure Microbiologic cure
Regimen Number of
studies
Number of
patients Percent Number of
studies
Number of
patients Percent
Parenteral
Clindamycin/aminoglycoside 11 470 92 8 143 97
Cefoxitin/doxycycline 9 836 95 7 581 96
Cefotetan/doxycycline 3 174 94 2 71 100
Ciproﬂoxacin 4 90 94 4 72 96
Oﬂoxacin 2 86 99 2 50 98
Sulbactam-ampicillin/doxycycline 1 37 95 1 33 100
Metronidazole/doxycycline 2 36 75 1 7 71
Azithromycin 1 30 100 1 30 100
Azithromycin/metronidazole 1 30 97 1 30 97
Oral
Ceftriaxone/probenecid/doxycycline 1 64 95 1 8 100
Cefoxitin/probenecid/doxycycline 3 212 90 3 71 93
Cefoxitin/doxycycline 4 634 94 4 493 95
Amoxicillin-clavulanic acid 2 35 100 2 35+ 100
Ciproﬂoxacin/clindamycin 1 67 97 1 10 90
Oﬂoxacin 2 165 95 2 42+ 100
Levoﬂoxacin 1 41 85 1 9 89
Reprinted with permission from Walker and Sweet [64].
As noted by Walker and Wiesenfeld [17], there has
been renewed interest in alternative agents, particularly am-
picillin-sulbactam for anaerobic coverage. Unlike clinda-
mycin, this agent has not been associated with selective
pressure for microbial resistance. In addition, ampicillin-
sulbactam is eﬀective for N. gonorrhoeae.T op r o v i d ea d e -
quate coverage for C. trachomatis, concomitant adminis-
tration of doxycycline is recommended. Following clinical
improvement, oral therapy with doxycycline 100mg twice
a day to complete 14 days of therapy should be continued.
With severe disease, especially TOA, metronidazole 500mg
orally four times daily should be commenced as well.
While not included in the CDC 2010 recommended or
alternative regimens for the treatment of PID, several factors
have led clinicians to use azithromycin for the treatment
of acute PID. These include widespread use in treating
chlamydial infection, enhanced compliance due to its long
half-life, and studies demonstrating the anti-inﬂammatory
eﬀectsofmacrolideantibioticsincludingazithromycinwhich
appeartoenhancehostdefensemechanismsandrestrictlocal
inﬂammation [17, 18, 75, 76]. A randomized clinical trial
in the United Kingdom among 300 women with laparo-
scopically conﬁrmed PID demonstrated excellent short-term
clinical care rates with azithromycin monotherapy for one
week (500mg IV daily for one or two days followed by
250mg for 5-6 days) or in combination with a 12 day course
of metronidazole [77]. The microbiologic cure rates were
also excellent (>95%) for N. gonorrhoeae, C. trachomatis,
M. hominis, and anaerobes with these regimens. However,
there was a large dropout rate with only one-third of the
patients completing the study per protocol which, as noted
by Haggerty and Ness [18] reduced the validity and general-
izability of the microbiological cure evaluation. In addition,
the anaerobic bacteria were only recovered from 27 (9%) of
the patients, a rate substantially lower than noted in other
studies.
The 2007 European guideline for the management of
pelvic inﬂammatory disease contains similar recommenda-
tions [2].
As alternative regimens, the European guideline suggests
i.v. oﬂoxacin 400mg twice daily plus i.v. metronidazole
500mg three times daily for 14 days or i.v. ciproﬂoxacin
200mg twice daily plus i.v. (or oral) doxycycline 100mg
twice daily plus i.v. metronidazole 500mg three times daily
[2]. Because anaerobes are probably of relatively greater
importance in patients with severe PID and some studies
have demonstrated good clinical response without the use
of metronidazole, the European guideline suggests that
metronidazole may be discontinued in those patients with
mild or moderate PID who are unable to tolerate it [2].
They further note that oﬂoxacin and moxiﬂoxacin should be
avoided in patients who are at high risk of gonococcal PID
due to increasing quinolone resistance by N. gonorrhoeae.
4.2. Oral Treatment. Over the past 20 years, a new paradigm
has emerged with a dramatic shift from hospital-based
parenteral antibiotic regimens to oral ambulatory-based
regimens [6, 7]. Initially, this shift was largely driven by the
emergence of managed care and other economic factors
withoutthebeneﬁtofclinicalstudiesdemonstratingthatoral8 Infectious Diseases in Obstetrics and Gynecology
therapy was as eﬀective as parenteral regimens, especially for
prevention of long-term sequelae.
The PEACH study has provided evidence supporting the
useoforalregimensonanambulatorybasisforthetreatment
of mild and moderately severe acute PID [42, 78]. PEACH,
the largest randomized clinical treatment trial of acute
PID in the United States, compared inpatient parenteral
therapy (intravenous cefoxitin and oral or intravenous
doxycycline during ≥48-hour hospitalization followed by
oraldoxycyclinetocompletea14daycourse)withoutpatient
oral therapy (a single intramuscular dose of cefoxitin with
doxycycline administration orally for 14-days). Of most
signiﬁcance, PEACH not only assessed short-term but also
long-term outcomes for over 800 patients (398 inpatient
and 410 outpatient) with mild-to-moderately severe PID.
The short-term clinical cure rates at 30 days were excellent
in both groups, with roughly 3% of women in each group
requiring additional treatment. At a mean followup of 35
months, the pregnancy rates were 42.0% and 41.7% with the
outpatient and inpatient regimens, respectively. Long-term
outcomes including infertility, ectopic pregnancy, recurrent
PID, and chronic pelvic pain were also similar in both
groups. However, as emphasized by Haggerty and Ness,
despite high rates of clinical cure and eradication of N.
gonorrhoeae and C.trachomatis, the rates of infertility (17%),
recurrent PID (14%), and chronic pelvic pain (37%) were
disappointingly high [18].
While data from the PEACH study suggests that neither
the route nor site of treatment administration aﬀects short-
term or long-term outcomes among women with mild-to-
moderately severe acute PID [42, 78], higher rates of post
treatment histologic endometritis were present among the
women in the outpatient oral group. However, the clinical
signiﬁcance of this ﬁnding is not clear. In previous studies we
have shown that ongoing subclinical PID (as deﬁned by his-
tologic acute endometritis) is frequently present in women
with untreated lower genital tract infections [14], and that
persistentendometrialinfectionwithC.trachomatis[26]and
anaerobes [22] may lead to subsequent tubal damage and
increasedinfertilityamongwomenwithinadequatelytreated
acute PID. Similarly, among women enrolled in the PEACH
study, 23 out of 56 (41%) with M. genitalium identiﬁed in
either the cervix and/or endometrium at baseline had M.
genitaliumpersistentlyidentiﬁed30daysfollowingtreatment
(inadequate to treat this organism) [40]. Moreover, women
with persistent endometrial M. genitalium were 4.5 times
more likely to experience short-term treatment failure (i.e.,
histologic endometritis and persistent pelvic pain at the 30-
day follow-up visit).
As noted by the CDC [1], outpatient oral therapy can
be considered for treatment of women with mild-to-mod-
erately severe acute PID. The oral regimens listed in Table 3
provide coverage against the major etiologic agents of
acute PID. Which of the cephalosporins is the optimum
selection is unclear [1]. On the one hand cefoxitin has
better anaerobic coverage, while ceftriaxone has better cov-
erage against N. gonorrhoeae. The dose of ceftriaxone was
increased to 250mg IM in the 2010 CDC guidelines [1].
The extent of eﬃcacy against anaerobic bacteria with a
single dose of cefoxitin is questionable. However, in the
PEACH study single dose cefoxitin was eﬀective in obtaining
clinical response [42, 78]. The CDC [1] and Walker and
Wiesenfeld [17] have noted that theoretical limitations in
coverage of anaerobes by recommended cephalosporins may
require addition of metronidazole to the oral treatment rec-
ommendations. Addition of metronidazole to the oral reg-
imens is the author’s preferred approach. In addition, met-
ronidazole will eﬀectively treat bacterial vaginosis, which
as noted above is frequently associated with PID. There is
no published data on the use of oral cephalosporins for
treatment of acute PID [1].
Information regarding alternative oral (outpatient) reg-
imens is quite limited. Several alternative regimens have
been the subject of at least one clinical trial and contain
broad spectrum coverage [1]. These include (1) amox-
icillin/clavulanic acid and doxycycline [79] and (2) Azith-
romycin monotherapy [77] or a combination of ceftriaxone
250mg IM single dose with azithromycin 1 gram orally
once a week for two weeks [80]. If one of these alternative
regimens is selected, the CDC suggests the addition of
metronidazole should be considered to cover anaerobic
bacteria which are suspected as etiologic agents in PID and
to eﬀectively treat concomitant BV [1].
With the emergence of quinolone-resistant N. gonor-
rhoeae,regimensthatincludeaquinoloneagentarenolonger
recommended by the CDC for treatment of acute PID [1].
They note that in situations where single dose parenteral
cephalosporin is not feasible, use of ﬂuoroquinolones (lev-
oﬂoxacin 500mg orally once a day or oﬂoxacin 400mg orally
twice a day for 14 days) with or without metronidazole
(500mg twice daily for 14 days) can be considered if
community prevalence and individual risk for gonorrhea are
low [1]. If this approach is selected, the CDC stresses that
diagnostic tests for N. gonorrhoeae must be performed prior
to initiating treatment [1]. Culture is the preferred test. If
N. gonorrhoeae is detected, treatment should be based on
the results of antimicrobial susceptibility. With quinolone-
resistantN.gonorrhoeaeorifsusceptibilitycannotbeassessed
(e.g., nucleic acid ampliﬁcation test) use of a parenteral
cephalosporin is recommended [1]. If use of a cephalosporin
is not feasible, azithromycin 2 grams as a single dose can be
added to a quinolone-based PID treatment regimen [1].
Patients treated with an oral regimen should demon-
strate substantial clinical improvement within three days
following initiation of treatment [1]. Clinical improvement
is determined by defervescence, reduction in direct or
rebound abdominal tenderness, and/or reduction in uterine,
adnexal, and cervical motion tenderness. When patients fail
to improve within this window, hospitalization is usually
required for additional diagnostic tests (e.g., rule out TOA),
parenteral antibiotic therapy, and/or surgical intervention
[1].
4.3. Hospitalization for Treatment of Acute PID. While in
the past, and to a lesser extent today, some clinicians have
recommended that all patients with PID be hospitalized for
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Table 5:Suggestedcriteriaforhospitalizationfortreatmentofacute
PIDa.
(i) Surgical emergencies (e.g, appendicitis) cannot be ruled out
(ii) Patient is pregnant
(iii) Patient does not respond clinically to oral antimicrobial
therapy
(iv) Patient unable to follow or tolerate outpatient oral regimen
(v) Patient has severe illness, nausea, vomiting, or high fever
(vi) Patient has a tuboovarian abscess
aCDC Sexually Transmitted Diseases Treatment Guidelines 2010 MMWR
2010:59 (no.-RR12).
demonstrated that in women with mild-to-moderately
severe PID, outpatient oral therapy results in similar short-
and long-term clinical outcomes as inpatient therapy [42].
As a result, the CDC notes that a decision regarding the need
for hospitalization should be based on the judgment of the
health-care provider and whether the patient meets any of
theCDCsuggestedcriteriaforhospitalizations(Table 5).The
European guideline concurs with these recommendations
[2].
Limitedstudieshavedemonstratedthatpregnantwomen
with PID have high rates of fetal wastage and preterm
delivery, supporting the appropriateness of hospitalization
[81, 82]. Similarly, ample data supports hospitalization of
women with TOAs in order to maximize antimicrobial
dosing and close monitoring for early recognition of severe
sepsis or of leaking/rupture of the abscess.
Several previous criteria for hospitalization have been
removed from the current suggestions. The absence of data
to support beneﬁt from hospitalization for adolescent girls
with PID led the CDC to not list adolescence among the
criteria for hospitalization and to suggest that a decision
to hospitalize adolescents with PID should be based on the
same criteria used for older women [1]. In fact, subanalysis
of the outcome data of the PEACH study stratiﬁed by
age demonstrated that fertility outcomes of the adolescents
were similar in the inpatient and outpatient treatment arms
[78]. However, some clinicians continue to advocate that
all adolescents and never pregnant young women should be
hospitalized for treatment [83]. They argue that adolescence
is a proxy for poor compliance, high-risk sexual activity,
delayed care, and high antimicrobial failure rates.
Whereas the presence of HIV infection or immunosup-
pression has previously been an indicator for hospitalization
and parenteral therapy, currently it is recommended that
HIV-positive women with acute PID can be treated similarly
to HIV-negative women. Although HIV-infected women
whodevelopPIDmayhavemoresevereclinicalpresentations
and are more likely to have TOAs [84–86], there is no evi-
dence to suggest that immunocompromised women beneﬁt
from hospitalization or parenteral therapy for uncompli-
cated PID [17, 87, 88].
4.4. Management of PID Associated with Intrauterine Contra-
ceptive Device (IUD). With the renewed interest in the IUD
as a contraceptive choice for young women, PID will be seen
in women using IUDs. As noted by Walker and Wiesenfeld,
there does not exist any data to indicate that selection of
treatment regimens should be inﬂuenced by the presence
of an IUD [17]. In the past, clinicians generally removed
IUDs to optimize the treatment of PID. This was primarily
based on concerns that as a foreign body, removal of the
IUD enhanced clinical response. Only a few studies have
addressed this issue and the results are conﬂicting. In a small
randomized study of 46 women in Sweden, Soderberg, and
Lindgren [89]r e p o r t e dn od i ﬀerences in response to treat-
ment whether the IUD was removed or left in place. On the
other hand, Altunyurt and colleagues, in a randomized trial
from Turkey, noted that clinical improvement (e.g., absence
of pelvic pain, vaginal discharge, and pelvic tenderness) was
more common in the group whose IUDs were removed [90].
If the provider elects to leave the IUD in place while PID is
being treated, close clinical followup is important.
4.5. Management of Sex Partners. According to the CDC,
male sex partners of women diagnosed with acute PID
should be examined and treated if they had sexual contact
with the patient during the preceding 60 days. If the last
episode of sexual intercourse was > 60 days prior to onset
of symptoms, the last sexual partner should be treated
[1]. Women diagnosed with acute PID should refrain from
sexual intercourse until treatment is completed and they and
their partner(s) are asymptomatic. Sex partners of women
with PID should be treated empirically with regimens
eﬀective against N. gonorrhoeae and C. trachomatis [1]. In
those settings where only women are treated, arrangements
should be undertaken to either provide care or appropriate
referral for male sex partners [1]. Expedited partner treat-
ment or enhanced patient referral are acceptable alternative
approachesforthetreatmentofmalepartnersofwomenwho
have PID with chlamydial or gonococcal infection [1].
5. Conclusion
Treatment strategies for women with acute PID should
be based on the polymicrobial nature of this infection.
The microorganisms recovered from the upper genital tract
of women with acute PID include N. gonorrhoeae, C.
trachomatis, and anaerobic and aerobic bacteria common
to the endogenous vaginal ﬂora and genital mycoplasmas,
especially M. genitalium. Several antibiotic regimens are
available which meet these requirements. Several parenteral
antimicrobial regimens have been shown to provide very
good short-term clinical and microbiological eﬃcacy; these
include clindamycin plus gentamicin, cefoxitin plus doxycy-
cline, and cefotetan plus doxycycline.
Oral therapy for acute PID is currently the most com-
monly used approach, in response to both economic issues
and the evidence from the PEACH study demonstrating
that both short-term and long-term outcomes were similar
for the oral and parenteral regimens. Due to the increased
quinolone resistance of N. gonorrhoeae, choices of oral
regimens are more limited. Ceftriaxone or cefoxitin demon-
strated excellent short-term clinical and microbiological
results. The addition of oral metronidazole to this regimen10 Infectious Diseases in Obstetrics and Gynecology
is suggested by some experts including this author to provide
improved anaerobic coverage and at least to treat BV which
is present in up to 70% of women with acute PID.
Currently regimens recommended by the CDC for the
treatment of acute PID provide suboptimal antimicrobial
activity against M. genitalium [40]. Mycoplasma lack a
cell wall and thus are resistant to beta-lactam antibiotics
(e.g., cefoxitin, cefotetan, ceftriaxone). Increased tetracycline
resistance among M. genitalium has been reported [91].
In addition, M. genitalium is associated with persistent
nongonococcal urethritis treated with tetracyclines [92].
Variable resistance to ﬂuoroquinolones has been reported
[93]. Recently, a newer ﬂuoroquinolone, moxiﬂoxacin, has
demonstrated excellent activity against M. genitalium [91,
93]. This agent is one of the outpatient regimens recom-
mended in the European guidelines [2]. While M. genitalium
has demonstrated susceptibility to macrolides, azithromycin
resistance has recently been reported [94].
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